Cowen analyst Tyler Van Buren downgraded Fate Therapeutics to Market Perform from Outperform without a price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FATE:
- Here’s Why Fate Therapeutics (NASDAQ:FATE) Stock Is Sliding Down
- Fate Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Fate Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- Fate Therapeutics downgraded to Hold from Buy at Truist
- Fate Therapeutics down 45% on termination of collaboration pact with Janssen